The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Celgene Corporation to Present at the Credit Suisse 2011 Healthcare Conference

Thursday, November 03, 2011

Celgene Corporation to Present at the Credit Suisse 2011 Healthcare Conference07:30 EDT Thursday, November 03, 2011 SUMMIT, N.J. (Business Wire) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Credit Suisse 2011 Healthcare Conference on Friday, November 11, 2011 at 11:30am ET will be webcast live and will be available in the investor relations section of the company's Web site at Celgene management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission. Celgene CorporationJacqualyn A. Fouse, 908-673-9956Sr. Vice President andChief Financial OfficerorPatrick E. Flanigan III, 908-673-9969Vice PresidentInvestor Relations